Infections invasives à méningocoque de groupe b: un problème de santé publique non résolu [Group B meningococcal invasive infections: an unresolved public health problem]

Details

Serval ID
serval:BIB_F0A03728E559
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Infections invasives à méningocoque de groupe b: un problème de santé publique non résolu [Group B meningococcal invasive infections: an unresolved public health problem]
Journal
Revue medicale suisse
Author(s)
Crisinel P.A., Posfay-Barbe K.M.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
23/02/2011
Peer-reviewed
Oui
Volume
7
Number
283
Pages
447-450
Language
french
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Abstract
Group B meningococcal infections represent 64% of the invasive meningococcal infections in Switzerland. While conjugate vaccine against group C meningococcus is part of the additional vaccinations of the Swiss vaccinal calendar and quadrivalent vaccines protect against serogroups A, C, Y, and W135, there is presently no available vaccine against group B meningococcus in Switzerland. The use of the capsular polysaccharide from the group B meningococcus is ineffective and possibly dangerous because of its similarity with an adhesion molecule of the human neuronal cells. Development of new vaccines with other antigenic targets gives hope for an optimal protection not only against group B meningococcus, but also against other serogroups that share same antigenic determinants.
Keywords
Humans, Meningitis, Meningococcal/immunology, Meningitis, Meningococcal/prevention & control, Meningococcal Infections/epidemiology, Meningococcal Infections/immunology, Meningococcal Infections/microbiology, Meningococcal Infections/prevention & control, Meningococcal Vaccines/administration & dosage, Meningococcal Vaccines/adverse effects, Neisseria meningitidis, Serogroup B/isolation & purification, Neisseria meningitidis, Serogroup B/pathogenicity, Public Health, Switzerland/epidemiology
Pubmed
Create date
03/06/2020 8:37
Last modification date
28/05/2024 17:06
Usage data